Miami, FL – The Diabetes Research Institute Foundation (DRIF) is pleased to announce significant findings that could impact the future of type 1 diabetes (T1D) and beta cell replacement therapies.
A recent study by scientists at the DRI led by Dr. Peter Buchwald has shown that two new small-molecule drugs (DRI-C21041 and DRI-C21095) designed, synthesized, and tested by them may help protect transplanted insulin-producing cells and prevent the onset of type 1 diabetes. These molecules work by targeting a specific immune checkpoint interaction in the immune system that is known to play a critical role in initiating the rejection of transplanted cells and the onset of autoimmune attacks on the body’s own cells.
What This Means for Type 1 Diabetes and Transplant Patients
For individuals with T1D, the immune system mistakenly destroys the insulin-producing cells in the pancreas. This study suggests that by blocking the CD40–CD40L interaction (a pathway involved in the activation of immune attacks), these molecules could prevent T1D from developing in individuals at high risk. In a pre-clinical small model, one of the molecules reduced diabetes cases from 80% to 25%, showing a significant impact on disease prevention.
For transplantation, these molecules could offer a new way to protect transplanted cells, such as insulin-producing cells used in T1D treatment. Unlike traditional therapies, these small molecules are potentially safer and less immunogenic (less likely to trigger an unwanted immune response), and they could be more easily administered as pills rather than injections. This is especially important for people with T1D who may need to take immune-suppressing medications for long periods to protect transplanted cells.
The Future of Diabetes Research and Patient Care
This encouraging research, supported by the DRIF, suggests a new path for therapies that are safer, easier, and potentially more effective than existing ones for individuals with T1D and transplant recipients. These findings open doors for future studies and could ultimately lead to the development of treatments that prevent diabetes and protect transplants long term by inducing operational immune tolerance without the risks associated with current immunosuppressive drugs.
As we move forward, the DRI continues to seek innovative solutions to prevent and cure diabetes, and we remain dedicated to improving the lives of those affected by this condition.
For more information on this study and to learn how you can support diabetes research, visit https://diabetesresearch.org
Longitudinal images showing a rejected islet (top row) and an islet treated with the small molecule DRI-C21041, which maintained integrity without rejection even after treatment stopped on post-operative day 60 (POD60) (bottom row).